imatinib mesylate has been researched along with Anemia in 32 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (25.00) | 29.6817 |
| 2010's | 16 (50.00) | 24.3611 |
| 2020's | 8 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bett, Y; Ezzi, M; McLigeyo, A; Mwanzi, S; Odhiambo, A; Ong'ondi, M; Othieno-Abinya, N; Oyiro, P; Rajab, J | 1 |
| Agrawal, N; Ahmed, R; Bhurani, D; Kumar, A; Sharma, M; Singh, AK | 1 |
| Briant, A; Brossier, D; De Moerloose, B; Delehaye, F; Dworzak, M; Güneş, AM; Hraskova, A; Kalwak, K; Lausen, B; Li, CK; Millot, F; Parienti, JJ; Rouger, J; Roula, F; Sedlacek, P; Srdjana, C; Suttorp, M; Versluys, B | 1 |
| Agrawal, N; Ahmed, R; Bhurani, D; Sharma, M; Singh, AK; Vidyadhari, A | 1 |
| Ansari, R; Taghizadeh-Ghehi, M | 1 |
| Alimena, G; Breccia, M; Carmosino, I; Cesini, L; Colafigli, G; De Benedittis, D; De Luca, ML; Diverio, D; Foà, R; Latagliata, R; Loglisci, MG; Mancini, M; Mariggiò, E; Massaro, F; Mohamed, S; Molica, M; Rizzo, L; Scalzulli, E; Scamuffa, MC; Vozella, F | 1 |
| Aguzzi, C; Aprile, L; Baratè, C; Bergamaschi, M; Bocchia, M; Bonifacio, M; Breccia, M; Cagnetta, A; Capodanno, I; Carmosino, I; Cerrano, M; Cesini, L; Crugnola, M; Elena, C; Frieri, C; Galimberti, S; Gozzini, A; Latagliata, R; Luciano, L; Ricci, F; Scalzulli, E; Sgherza, N; Sica, S; Sorà, F; Trawinska, M | 1 |
| Doi, S; Hamada, T; Kato, K; Kishimoto, W; Moriguchi, T; Tashiro, Y; Ueda, C; Yoshinaga, N | 1 |
| Li, J; Li, Y; Liu, X; Shen, L; Wu, X; Zhang, B; Zhang, X; Zhou, Y | 1 |
| Chen, PM; Chiou, TJ; Gau, JP; Hsiao, LT; Hung, MH; Ko, PS; Liu, CJ; Liu, CY; Liu, JH; Liu, YC; Wu, YT; Yu, YB | 1 |
| Ghirdaladze, D; Kirtava, T; Vatsadze, T | 1 |
| Abbasi, S; Alrabi, K; Awidi, A; Kheirallah, KA | 1 |
| Abe, R; Hashida, R; Karigane, D; Kasahara, H; Kato, J; Kikuchi, T; Koda, Y; Matsuki, E; Mori, T; Nakamura, T; Okamoto, S; Sakurai, M; Shimizu, T; Suzuki, S; Toyama, T; Yamane, Y; Yokoyama, Y | 1 |
| Alimena, G; Breccia, M; Carmosino, I; Finsinger, P; Latagliata, R; Molica, M; Montagna, C; Romano, A; Salaroli, A; Santopietro, M; Serrao, A; Volpicelli, P; Vozella, F; Zacheo, I | 1 |
| Du, Z; Lyu, Z; Pan, Y; Tian, J; Wen, S; Yan, L | 1 |
| DU, X; Han, X; Hou, M; Hu, J; Jiang, Q; Jin, J; Li, Y; Liu, B; Liu, T; Ma, J; Meng, F; Shen, Z; Wu, D; Zhao, D | 1 |
| Alimena, G; Breccia, M | 1 |
| Daniels, CE; Gabor, E; Lasky, JA; Limper, AH; Mieras, K; Schroeder, DR | 1 |
| Calbacho, M; Cervantes, F; Colomer, D; González, M; Hernández-Boluda, JC; Jonte, F; López-Garrido, P; Martínez, J; Montero, MI; Nieto, JB; Pereira, A; Pérez-López, C; Pérez-Rus, G; Román-Gómez, J; Sureda, A | 1 |
| Bryan, J; Garcia-Manero, G; Issa, JP; Jabbour, E; Kantarjian, H; Prescott, H | 1 |
| Alvarado, Y; Borthakur, G; Cortes, J; Kantarjian, H; Mattiuzzi, G; O'Brien, S; Ravandi, F; Santos, FP; Verma, D | 1 |
| Allard, C; Berger, M; Berthou, C; Coiteux, V; Corm, S; Delmer, A; Eclache, V; Etienne, G; Gardembas, M; Guerci-Bresler, A; Guilhot, F; Guilhot, J; Jourdan, E; Legros, L; Mahon, FX; Maloisel, F; Nicolini, FE; Preudhomme, C; Rea, D; Rigal-Huguet, F; Roche-Lestienne, C; Rousselot, P; Vekhoff, A | 1 |
| de Leon, F; McBain, D; Petrlich, L; Pope, J; Seney, S; Summers, K; Vanderhoek, L; Watson, S | 1 |
| Baybay, H; Berrady, R; Bono, W; El Hatimi, A; Gallouj, S; Khammar, Z; Lahlou, M; Lamchachti, L; Mernissi, FZ | 1 |
| Abraham, LJ; Appaji, L; Arunakumari, BS; Bhise, R; Govindbabu, K; Lakshmaiah, KC; Lokanatha, D; Purohit, S; Suresh, TM | 1 |
| Hoffer, FA; Jenkins, JJ; Lobe, TE; Lowe, EJ; Santana, VM | 1 |
| Cortes, J; Giles, F; Kantarjian, H; O'Brien, S; Quintas, A; Rios, MB; Shan, J; Talpaz, M | 1 |
| Durham, MM; Gow, KW; Katzenstein, HM; Lorenzo, RL; Ricketts, RR; Shehata, BM | 1 |
| Champlin, R; Cortes, J; de Lima, M; Faderl, S; Garcia-Manero, G; Giles, F; Kantarjian, H; O'Brien, S; Rios, MB; Shan, J; Talpaz, M; Verstovsek, S | 1 |
| Azuma, M; Higuchi, K; Katada, C; Koizumi, W; Nakatani, K; Nishimura, K; Saigenji, K; Sasaki, T; Shimoda, T; Tanabe, S | 1 |
| Bosi, E; Davalli, AM; Folli, F; Galimberti, G; Pastore, M | 1 |
| Cortes, J; Estrov, Z; Faderl, S; Garcia-Manero, G; Giles, F; Kantarjian, H; Ladie, N; Murgo, A; O'Brien, S; Quintás-Cardama, A; Verstovsek, S | 1 |
2 review(s) available for imatinib mesylate and Anemia
| Article | Year |
|---|---|
Prevalence of Anemia among Chronic Myeloid Leukemia Patients Treated with Imatinib: A Evidence-based Meta-analysis.
Topics: Anemia; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Prevalence; Protein Kinase Inhibitors; Pyrimidines | 2023 |
Current and future management options for myelodysplastic syndromes.
Topics: Adenine Nucleotides; Anemia; Arabinonucleosides; Benzamides; Bone Marrow; Clofarabine; DNA Methylation; Drugs, Investigational; Farnesyltranstransferase; Histone Deacetylase Inhibitors; Humans; Imatinib Mesylate; Immunosuppressive Agents; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Receptors, Fc; Recombinant Fusion Proteins; Risk Factors; Thalidomide; Thrombopoietin | 2010 |
8 trial(s) available for imatinib mesylate and Anemia
| Article | Year |
|---|---|
A prospective multicenter phase II study on the efficacy and safety of dasatinib in the treatment of metastatic gastrointestinal stromal tumors failed by imatinib and sunitinib and analysis of NGS in peripheral blood.
Topics: Administration, Oral; Adult; Aged; Anemia; Antineoplastic Agents; Dasatinib; Diarrhea; DNA Copy Number Variations; Drug Administration Schedule; Fatigue; Female; Gastrointestinal Stromal Tumors; Genotype; High-Throughput Nucleotide Sequencing; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Neutropenia; Progression-Free Survival; Prospective Studies; Protein Kinase Inhibitors; Proteinuria; Sunitinib | 2020 |
Renal dysfunction and anemia associated with long-term imatinib treatment in patients with chronic myelogenous leukemia.
Topics: Adult; Aged; Anemia; Female; Follow-Up Studies; Hemoglobins; Humans; Imatinib Mesylate; Kidney Diseases; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Retrospective Studies; Time Factors | 2019 |
[A prospective, multi-centre clinical trial to evaluate the early clinical efficacy and safety of a generic imatinib in treating patients with chronic phase of chronic myelogenous leukemia].
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Cytogenetics; Drugs, Generic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Prospective Studies; Protein Kinase Inhibitors; Remission Induction; Thrombocytopenia; Treatment Outcome | 2015 |
Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results.
Topics: Aged; Anemia; Benzamides; Disease Progression; Double-Blind Method; Dyspnea; Feasibility Studies; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematoma, Subdural; Humans; Idiopathic Pulmonary Fibrosis; Imatinib Mesylate; Leukopenia; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Respiratory Function Tests; Survival Analysis; Treatment Outcome | 2010 |
Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group.
Topics: Adolescent; Adult; Aged; Anemia; Antineoplastic Agents; Benzamides; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Neutropenia; Piperazines; Pyrimidines; Spain; Thrombocytopenia; Time Factors; Treatment Outcome; Young Adult | 2010 |
Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.
Topics: Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon alpha-2; Interferon-alpha; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Neutropenia; Piperazines; Polyethylene Glycols; Proto-Oncogene Proteins c-abl; Pyrimidines; Recombinant Proteins; Remission Induction; RNA, Neoplasm; Stem Cells; Survival Analysis; Thrombocytopenia; Transcription, Genetic; Treatment Outcome | 2010 |
Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center.
Topics: Adult; Aged; Alopecia; Anemia; Benzamides; Diarrhea; Double-Blind Method; Early Termination of Clinical Trials; Edema; Female; Humans; Imatinib Mesylate; Male; Middle Aged; Nausea; Pilot Projects; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Scleroderma, Diffuse; Surveys and Questionnaires; Treatment Outcome | 2011 |
Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy.
Topics: Adult; Aged; Anemia; Antineoplastic Agents, Phytogenic; Benzamides; Blast Crisis; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Harringtonines; Homoharringtonine; Humans; Imatinib Mesylate; Injections, Intravenous; Injections, Subcutaneous; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nausea; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Treatment Failure; Treatment Outcome | 2007 |
22 other study(ies) available for imatinib mesylate and Anemia
| Article | Year |
|---|---|
Baseline blood count levels increase odds of cytopenia among CML patients in Kenya: a case control study.
Topics: Adolescent; Adult; Aged; Anemia; Antineoplastic Agents; Female; Humans; Imatinib Mesylate; Kenya; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Logistic Models; Male; Middle Aged; Multivariate Analysis; Neutropenia; Retrospective Studies; Thrombocytopenia; Treatment Outcome; Young Adult | 2022 |
Prevalence of anemia at diagnosis of pediatric chronic myeloid leukemia and prognostic impact on the disease course.
Topics: Adolescent; Adult; Anemia; Antineoplastic Agents; Child; Hemoglobins; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Prevalence; Prognosis; Protein Kinase Inhibitors | 2023 |
Effect of Imatinib treatment on renal anaemia in chronic myeloid leukemia patients.
Topics: Anemia; Antineoplastic Agents; Hemoglobins; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Renal Insufficiency, Chronic | 2023 |
Comment on "Effect of imatinib treatment on renal anemia in chronic myeloid leukemia patients".
Topics: Anemia; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2023 |
Incidence of Clinically Significant (≤10 g/dL) Late Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib.
Topics: Age Factors; Aged; Aged, 80 and over; Anemia; Erythrocyte Transfusion; Erythropoietin; Female; Humans; Imatinib Mesylate; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Recombinant Proteins; Retrospective Studies; Treatment Outcome | 2019 |
Erythropoietin treatment in chronic phase chronic myeloid leukemia patients treated with frontline imatinib who developed late anemia.
Topics: Aged; Anemia; Antineoplastic Agents; Biomarkers; Disease Management; Disease Susceptibility; Erythrocyte Indices; Erythropoietin; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Protein Kinase Inhibitors; Treatment Outcome | 2020 |
[BCR-ABL1-positive myelodysplastic syndrome with neutropenia and anemia treated successfully with imatinib mesylate].
Topics: Aged, 80 and over; Anemia; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Myelodysplastic Syndromes; Neutropenia; Protein Kinase Inhibitors | 2020 |
Moderate anemia at diagnosis is an independent prognostic marker of the EUTOS, Sokal, and Hasford scores for survival and treatment response in chronic-phase, chronic myeloid leukemia patients with frontline imatinib.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia; Benzamides; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Monitoring, Physiologic; Prognosis; Retrospective Studies; Treatment Outcome; Young Adult | 2017 |
CHRONIC MYELOID LEUKEMIA EXPECTED RELAPSE'S CLINICAL-LABORATORY INDEXES.
Topics: Anemia; Antineoplastic Agents; Blood Platelets; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medication Adherence; Prognosis; Recurrence; Retrospective Studies; Risk | 2017 |
Generic Imatinib Therapy Among Jordanians: An Observational Assessment of Efficacy and Safety in Routine Clinical Practice.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Drugs, Generic; Eye Diseases; Female; Humans; Imatinib Mesylate; Jordan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nausea; Practice Patterns, Physicians'; Prospective Studies; Treatment Outcome; Young Adult | 2017 |
Incidence of persistent/late chronic anemia in newly diagnosed patients with chronic myeloid leukemia responsive to imatinib.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Benzamides; Chronic Disease; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Remission Induction; Reticulocytes; Severity of Illness Index; Sex Factors; Survival Analysis | 2015 |
[Imatinib is effective in a 12-month-old boy with chronic myelogenous leukemia: case report and literature review].
Topics: Anemia; Antineoplastic Agents; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Remission Induction; Retrospective Studies | 2015 |
Are there new clinical parameters useful to predict response in chronic myeloid leukemia in the imatinib era?
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Benzamides; Erythrocyte Indices; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Multivariate Analysis; Piperazines; Pyrimidines; Retrospective Studies | 2009 |
Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Benzamides; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Female; Hematinics; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Polypharmacy; Prognosis; Pyrimidines; Retrospective Studies; Survival Analysis; Thrombosis; Time Factors; Treatment Outcome; Young Adult | 2011 |
[Acquired ichthyosis and haematological malignancies: five cases].
Topics: Adult; Aged; Allopurinol; Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bleomycin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Hematologic Neoplasms; Hodgkin Disease; Humans; Ichthyosis; Imatinib Mesylate; Leukemia, Myeloid, Accelerated Phase; Lung Neoplasms; Lymphoma, B-Cell; Male; Middle Aged; Paraneoplastic Syndromes; Parotid Neoplasms; Piperazines; Platelet Aggregation Inhibitors; Prednisone; Procarbazine; Pyrimidines; Retrospective Studies; Rituximab; Schizophrenia; Stomach Neoplasms; Vincristine | 2012 |
Chronic myeloid leukemia in children and adolescents: results of treatment with imatinib mesylate.
Topics: Adolescent; Anemia; Antineoplastic Agents; Benzamides; Child; Exanthema; Female; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Nausea; Neutropenia; Piperazines; Pyrimidines; Remission Induction; Retrospective Studies; Treatment Outcome; Young Adult | 2012 |
Anemia and a large abdominal tumor in an adolescent.
Topics: Abdominal Muscles; Adolescent; Anemia; Antineoplastic Agents; Benzamides; Carcinoma; Combined Modality Therapy; Humans; Imatinib Mesylate; Magnetic Resonance Imaging; Male; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Stomach Neoplasms; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2004 |
Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase.
Topics: Anemia; Antineoplastic Agents; Benzamides; Erythropoietin; Female; Humans; Imatinib Mesylate; Injections, Subcutaneous; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Middle Aged; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Recombinant Proteins; Survival Rate; Treatment Outcome | 2004 |
Gastrointestinal stromal tumors arising from the stomach: a report of three children.
Topics: Abdominal Pain; Anemia; Benzamides; Chemotherapy, Adjuvant; Child; Child, Preschool; Female; Follow-Up Studies; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Laparotomy; Liver Neoplasms; Male; Piperazines; Pyrimidines; Radiography; Stomach Neoplasms | 2004 |
Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience.
Topics: Adult; Anemia; Antineoplastic Agents; Benzamides; Bone Marrow Transplantation; Cohort Studies; Cytogenetic Analysis; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Hemoglobins; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myeloid, Accelerated Phase; Longitudinal Studies; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Survival Rate; Treatment Outcome | 2005 |
[A gastric stromal tumor (GIST) with a prolonged partial response to a reduced dose of imatinib mesilate].
Topics: Aged; Anemia; Antineoplastic Agents; Benzamides; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukopenia; Liver Neoplasms; Piperazines; Pyrimidines; Stomach Neoplasms | 2006 |
Paraneoplastic insulin resistance syndrome in advanced aggressive fibromatosis (desmoid tumor) treated by imatinib mesylate.
Topics: Anemia; Benzamides; Female; Fibromatosis, Aggressive; Humans; Hypoglycemic Agents; Imatinib Mesylate; Insulin; Insulin Resistance; Leukopenia; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome | 2006 |